Economic evaluation of pharmacologic therapy

Area of Science:

• Pharmacoeconomics
• Health Economics
• Clinical Pharmacy

Background:

• Cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA) are crucial for evaluating pharmacologic therapies.
• CBA compares dissimilar alternatives, while CEA compares similar alternatives with shared objectives.
• CEA is valuable for identifying the most cost-efficient option to achieve a specific health outcome.

Purpose of the Study:

• To compare the cost-effectiveness of piperacillin versus cefoxitin in patients undergoing intraabdominal surgery.
• To evaluate the economic impact of antibiotic choice on patient outcomes and healthcare costs.

Main Methods:

• A cost-effectiveness analysis (CEA) was employed.
• Clinical trial data from 86 patients undergoing intraabdominal surgery were analyzed.
• Multivariate analysis was used to compare outcomes between piperacillin and cefoxitin treatment groups.

Main Results:

• Patients receiving piperacillin had significantly shorter hospital stays by 1.59 days compared to those treated with cefoxitin.
• Piperacillin treatment resulted in estimated savings of $680 per patient based on national average hospital per diem rates.
• Piperacillin was found to be less expensive than cefoxitin.

Conclusions:

• Piperacillin is a more cost-effective antibiotic option than cefoxitin for intraabdominal surgery.
• The use of piperacillin can lead to reduced hospital length of stay and significant cost savings in surgical patients.
• CEA provides valuable insights for optimizing pharmacologic therapy selection in clinical practice.